Antibody-Drug Conjugates in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Best practices when prescribing and managing antibody-drug conjugate therapy as treatment for relapsed/refractory diffuse large B-cell lymphoma.

EP. 1: Treatment Advances in Relapsed/Refractory DLBCL

July 13th 2021

A historical overview of treatment advances for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and the rationale for treating appropriate patients with an approved antibody-drug conjugate therapy.

EP. 2: Loncastuximab Tesirine for Relapsed/Refractory DLBCL

July 13th 2021

Potential implications for treating patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) with loncastuximab tesirine, an antibody-drug conjugate, based on early results demonstrated by the LOTIS-2 study.

EP. 3: Safety of Loncastuximab Tesirine for Relapsed/Refractory DLBCL

July 20th 2021

Recommendations for mitigating and managing common treatment-related adverse events associated with loncastuximab tesirine based on safety data from LOTIS-2 and variables that may impact patient candidacy.

EP. 4: Relapsed/Refractory DLBCL: Sequencing Therapy

July 20th 2021

Tycel Jovelle Phillips, MD, of the University of Michigan, comments on his preferences for treating patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and shares his expectations for sequencing with newer, novel approaches emerging in the field.

EP. 5: ADCs for Relapsed/Refractory DLBCL: Next Steps

July 20th 2021

Tycel Jovelle Phillips, MD, reviews current therapy options for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and how he selects among these options and highlights some potential new therapies.